Going beyond HbA1c to understand the benefits of advanced diabetes therapies

Journal of Diabetes
Robert Vigersky

Abstract

The gold standard for monitoring overall glycemia is HbA1c. However, HbA1c has several important limitations, giving more weight to the prior 2 to 3 months rather than short-term glycemic control. In addition, the level of the HbA1c does not reflect the important interpersonal differences in its relationship with mean glucose, and HbA1c is affected by many common clinical conditions (anemia, uremia) that can interfere with the accuracy of its measurement in the laboratory. The development and refinement of continuous glucose monitoring (CGM), a glucose- and patient-centric technology, over the past two decades have permitted the creation of new single and composite metrics, such as the percentage of time in range and the glucose pentagon, respectively, which provide clinically relevant insights into short-term glycemic control. In addition, CGM creates new outcome metrics for clinical management and investigational studies (percentage of time in hypoglycemia, percentage of time in target range) that can accurately and meaningfully report the effects of an intervention, whether that is a drug, a device, or a psychosocial program, and CGM provides the key input to drive algorithm-based insulin delivery. Finally, CGM linked with a...Continue Reading

References

Jul 13, 1974·Lancet·G Teasdale, B Jennett
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Jun 10, 2008·Diabetes Care·David M NathanUNKNOWN A1c-Derived Average Glucose Study Group
Jul 1, 2010·The New England Journal of Medicine·Richard M BergenstalUNKNOWN STAR 3 Study Group
Apr 10, 2013·Journal of Diabetes Science and Technology·Andreas LieblUNKNOWN Continuous Glucose Monitoring Working Group of the Working Group Diabetes Technology of the German Diabetes Association
Jun 25, 2013·The New England Journal of Medicine·Richard M BergenstalUNKNOWN ASPIRE In-Home Study Group
Nov 20, 2013·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Nicholas B ArgentoPeter Simpson
Jun 17, 2014·The New England Journal of Medicine·Steven J RussellEdward R Damiano
Sep 22, 2015·The Journal of Clinical Endocrinology and Metabolism·Signe RosenlundSteen Andersen
Feb 26, 2016·Diabetes Technology & Therapeutics·Pratik ChoudharyJohn J Shin
Sep 16, 2016·JAMA : the Journal of the American Medical Association·Richard M BergenstalFrancine R Kaufman
Jan 25, 2017·JAMA : the Journal of the American Medical Association·Roy W BeckUNKNOWN DIAMOND Study Group
Jul 28, 2017·Journal of Diabetes Science and Technology·Robert A VigerskyAndreas Thomas
Jul 28, 2017·Journal of Diabetes Science and Technology·Andreas ThomasRobert A Vigersky
Nov 23, 2017·Diabetes Care·Thomas DanneMoshe Phillip
Dec 10, 2017·Diabetes Care·UNKNOWN American Diabetes Association
May 23, 2018·Diabetes Care·UNKNOWN Beyond A1C Writing Group
Aug 31, 2018·Diabetes Technology & Therapeutics·Michael P StoneFrancine R Kaufman

❮ Previous
Next ❯

Citations

Feb 26, 2019·Journal of Diabetes·Zachary Bloomgarden
Aug 10, 2020·Clinical and Translational Science·Alan GodfreyElena S Izmailova
Mar 14, 2020·Therapeutic Advances in Chronic Disease·Chia-Lin LeeShang-Feng Tsai
Dec 29, 2020·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Sanjay KalraDiana A Nkansah
Feb 23, 2021·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·Rogério Tavares RibeiroJoão Filipe Raposo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.